Market Cap 690.41M
Revenue (ttm) 0.00
Net Income (ttm) -38.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 185,800
Avg Vol 255,588
Day's Range N/A - N/A
Shares Out 52.03M
Stochastic %K 62%
Beta 0.97
Analysts Strong Sell
Price Target $31.12

Company Profile

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 437 8334
Address:
Joshua Dawson House, Dawson Street, Dublin, Ireland
james2609
james2609 Oct. 25 at 6:06 AM
$GHRS buyout Monday
0 · Reply
patience_pays1
patience_pays1 Oct. 24 at 4:24 PM
$GHRS lets get buyout
0 · Reply
Doozio
Doozio Oct. 15 at 10:21 PM
$GHRS chop chop huckleberries……
0 · Reply
stoxx0007
stoxx0007 Oct. 14 at 11:50 PM
$GHRS $MNMD $CYBN $CMPS $PSIL Very Bold prediction right here.... And I agree 💯% ... 1,000% !!!🔥
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 10:11 AM
Needham updates rating for GH Research ( $GHRS ) to Buy, target set at 19.
0 · Reply
radhaswami8380
radhaswami8380 Oct. 9 at 12:31 PM
$NRXP The presentation yesterday was a hit with new investors, and we expect an announcement very soon. It's all about timing, and right now, the momentum is on our side. Just look at the string of good news from last month—this is another chance to get in on the ground floor. This stock is poised for a major move, with the potential to jump 20-25% in a day and continue climbing. The $40 price target isn't a guess; it's based on solid research. Remember, you can't rush a ripe mango. Great returns require patience, but for those who wait, the reward will be worth it. $GHRS $HUMA $ATAI
3 · Reply
Jason7847
Jason7847 Oct. 6 at 2:53 PM
$NRXP 1) NRx Pharmaceuticals’ recent FDA Fast Track designation for NRX-100 marks a major milestone that could accelerate the path to commercialization. 2) The company’s focus on innovative treatments for depression and suicidal ideation positions it as a potential leader in a critical and underserved market. 3) With growing regulatory momentum and strong clinical progress, NRXP appears well-placed to capture investor attention and long-term value. 4) Strategic partnerships and expanding clinical data could significantly enhance NRXP’s market credibility and growth prospects. 5) As mental health therapeutics gain global importance, NRx’s advanced drug pipeline represents a high-impact investment opportunity. 6) Positive FDA engagement and clinical advancements underscore NRXP’s potential for near-term catalysts and long-term growth. $ATAI $ICU $HUMA $GHRS
1 · Reply
Jason7847
Jason7847 Oct. 2 at 5:32 PM
$NRXP $6 by month-end, 200% upside possible by year-end. Big catalysts ahead. $ATAI $ICU $HUMA $GHRS
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 8:39 AM
$GHRS Excellent article that nails exactly where GHRS stands right now. So if you want to update your GHRS knowledge or get acquainted with GHRS, this is a must read. https://beyondspx.com/quote/GHRS/analysis/gh-research-pioneering-psychedelic-therapies-for-depression-s-unmet-needs-nasdaq-ghrs
0 · Reply
TalkMarkets
TalkMarkets Oct. 1 at 10:46 PM
Top 4 "Psych" Stocks Went Crazy In September Going Up +18% - Here's Why $ATAI $MNMD $CMPS $GHRS https://talkmarkets.com/content/stocks--equities/top-4-psych-stocks-went-crazy-in-september-going-up-18-heres-why?post=525544
0 · Reply
Latest News on GHRS
GH Research Announces Pricing of $150 Million Public Offering

Feb 4, 2025, 8:52 PM EST - 9 months ago

GH Research Announces Pricing of $150 Million Public Offering


GH Research Announces Proposed Public Offering

Feb 3, 2025, 4:03 PM EST - 9 months ago

GH Research Announces Proposed Public Offering


Why Is GH Research Stock Trading Higher On Monday?

Feb 3, 2025, 10:55 AM EST - 9 months ago

Why Is GH Research Stock Trading Higher On Monday?


GH Research: But Toad Venom Is A Controlled Substance

Jun 16, 2023, 11:06 AM EDT - 2 years ago

GH Research: But Toad Venom Is A Controlled Substance


Psychedelic Sunday: Competitive Strategies

Jan 15, 2023, 11:45 AM EST - 3 years ago

Psychedelic Sunday: Competitive Strategies

ATAI CMPS CYBN MNMD


GH Research Seeks $125 Million IPO

Jun 22, 2021, 8:25 PM EDT - 4 years ago

GH Research Seeks $125 Million IPO


james2609
james2609 Oct. 25 at 6:06 AM
$GHRS buyout Monday
0 · Reply
patience_pays1
patience_pays1 Oct. 24 at 4:24 PM
$GHRS lets get buyout
0 · Reply
Doozio
Doozio Oct. 15 at 10:21 PM
$GHRS chop chop huckleberries……
0 · Reply
stoxx0007
stoxx0007 Oct. 14 at 11:50 PM
$GHRS $MNMD $CYBN $CMPS $PSIL Very Bold prediction right here.... And I agree 💯% ... 1,000% !!!🔥
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 10:11 AM
Needham updates rating for GH Research ( $GHRS ) to Buy, target set at 19.
0 · Reply
radhaswami8380
radhaswami8380 Oct. 9 at 12:31 PM
$NRXP The presentation yesterday was a hit with new investors, and we expect an announcement very soon. It's all about timing, and right now, the momentum is on our side. Just look at the string of good news from last month—this is another chance to get in on the ground floor. This stock is poised for a major move, with the potential to jump 20-25% in a day and continue climbing. The $40 price target isn't a guess; it's based on solid research. Remember, you can't rush a ripe mango. Great returns require patience, but for those who wait, the reward will be worth it. $GHRS $HUMA $ATAI
3 · Reply
Jason7847
Jason7847 Oct. 6 at 2:53 PM
$NRXP 1) NRx Pharmaceuticals’ recent FDA Fast Track designation for NRX-100 marks a major milestone that could accelerate the path to commercialization. 2) The company’s focus on innovative treatments for depression and suicidal ideation positions it as a potential leader in a critical and underserved market. 3) With growing regulatory momentum and strong clinical progress, NRXP appears well-placed to capture investor attention and long-term value. 4) Strategic partnerships and expanding clinical data could significantly enhance NRXP’s market credibility and growth prospects. 5) As mental health therapeutics gain global importance, NRx’s advanced drug pipeline represents a high-impact investment opportunity. 6) Positive FDA engagement and clinical advancements underscore NRXP’s potential for near-term catalysts and long-term growth. $ATAI $ICU $HUMA $GHRS
1 · Reply
Jason7847
Jason7847 Oct. 2 at 5:32 PM
$NRXP $6 by month-end, 200% upside possible by year-end. Big catalysts ahead. $ATAI $ICU $HUMA $GHRS
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 8:39 AM
$GHRS Excellent article that nails exactly where GHRS stands right now. So if you want to update your GHRS knowledge or get acquainted with GHRS, this is a must read. https://beyondspx.com/quote/GHRS/analysis/gh-research-pioneering-psychedelic-therapies-for-depression-s-unmet-needs-nasdaq-ghrs
0 · Reply
TalkMarkets
TalkMarkets Oct. 1 at 10:46 PM
Top 4 "Psych" Stocks Went Crazy In September Going Up +18% - Here's Why $ATAI $MNMD $CMPS $GHRS https://talkmarkets.com/content/stocks--equities/top-4-psych-stocks-went-crazy-in-september-going-up-18-heres-why?post=525544
0 · Reply
Raxothus
Raxothus Sep. 29 at 7:55 PM
EOD CONTINUATION FOLLOW-UP – 09/29/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $MTEK – Dumped from 4.27 into the 2s on bad earnings. Full fade, failed continuation. ⚠️ $JUNS – Closed 1.60, reached 1.80 (+12.5%). Slow continuation, needs volume confirmation. ⚠️ $PRLD – Sideways action. No decisive continuation yet. ❌ $ELDN – Closed 2.67, slipped to 2.52. Weak, failed continuation. ⚠️ $GHRS – Sideways action. Neutral, watching for setup. Recap: 5 total → 1 winner, 2 fails, 2 neutral → 20% accuracy Leader: $JUNS (+12.5%) is the only valid continuation candidate, though momentum remains slow. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
0 · Reply
Raxothus
Raxothus Sep. 26 at 7:26 PM
EOD CONTINUATION WATCHLIST – 09/24/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $MTEK – 1.9x volume, 5.3% VWAP stretch, micro float (4.6M) 14.4% open-to-current with 6.1% late push, RSI 71.4. Strong candidate, watching breakout > 4.09 for continuation. $JUNS – 2.9x volume, 3.1% VWAP stretch, small float (16.2M) 17.8% open-to-current with 3.5% late push, RSI 56.2. Watching breakout > 1.66 for continuation. $PRLD – 2.4x volume, 12.2% VWAP stretch, small float (29.2M) 18.9% open-to-current with 5.1% late push, RSI 73.0. Strong mover, watching breakout > 1.45 for continuation. $ELDN – 4.7x volume, 2.4% VWAP stretch, small float (39.8M) 8.0% open-to-current with 0.9% late push, RSI 57.2. Watching breakout > 2.75 for continuation. $GHRS – 4.4x volume, 2.8% VWAP stretch, small float (20.5M) 7.0% open-to-current with 2.9% late push, RSI 67.3. Watching breakout > 14.62 for continuation. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #PowerHourWatch
0 · Reply
Quantumup
Quantumup Sep. 10 at 12:24 PM
Cantor Fitzgerald reiterated $GHRS Overweight/$25: $ATAI $JNJ $CMPS CYBN $MNMD A repeating theme we've heard in all of our webinars: Psychiatry is on the verge of delivering transformational value for millions of people in the U.S. (and millions more ex-U.S.) struggling with mental health conditions. Spravato is warming up the interventional psychiatry field. Of the 6000+ Spravato clinics, around half have gone online in the last 6 mos. Spravato is allowing clinics to understand the buy and bill system of the next wave of interventional therapies, as well as help iron out the CPT codes for reimbursement of healthcare practitioner time. Hospitals are interested in psychedelics too, not just interventional psychiatry clinics. Many have more capacity than people realize - with electroconvulsive therapy (ECT) falling out of favor, hospitals are exploring transitioning these rooms to psychedelic delivery suites.
1 · Reply
jmash
jmash Aug. 28 at 4:43 PM
$CMPS 5 is the level $ATAI $MNMD $GHRS
0 · Reply
TalkMarkets
TalkMarkets Aug. 19 at 7:47 PM
'Big 5" Psychedelic-Based #Biotech Stocks Up 34% YTD $ATAI $MNMD $CMPS $GHRS $CYBN https://talkmarkets.com/content/stocks--equities/big-5-psychedelic-based-biotech-stocks-up-34-ytd?post=516491
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Aug. 9 at 4:24 PM
$GHRS signal 64 %
0 · Reply
Quantumup
Quantumup Aug. 7 at 2:35 PM
Stifel reiterated $GHRS Buy/$32: "We're reiterating our Buy rating on $GHRS following 2Q25 earnings. Following a complete response to the FDA regarding the clinical hold on the IND for GH001, $GHRS recently disclosed that while the proprietary device has been cleared, FDA requested additional information regarding the rat-specific tox observed in preclinical studies. GH is consulting additional external experts here, but bottom line we believe with clear evidence suggesting this tox is specific to rats and with favorable patient data in hand from the ph2b in Europe (including 6-month OLE safety, with spirometry data), we continue to believe this will likely be resolved in the near-term. In addition to tailwinds for the psychedelic class more broadly, we believe $GHRS is well-positioned within the class with its compelling efficacy profile and ease-of-use. GH reiterated their plans to begin their pivotal program in TRD next year and are currently planning for their EoP2 meeting." $ATAI $JNJ
0 · Reply
TimRegan_WTR
TimRegan_WTR Jul. 25 at 2:40 PM
0 · Reply
JMAR_WTR
JMAR_WTR Jul. 25 at 2:22 PM
0 · Reply
research_WTR
research_WTR Jul. 25 at 2:19 PM
CYBN: CYB003 vs. GH001 New Data Alert: GH Research (NASDAQ: GHRS) released final 6-month data from its Phase 2b OLE study of GH001 for treatment-resistant depression (TRD), showing a 73% remission rate among completers. Including early dropouts, remission is still a solid ~57%. 🔹 90% of day-8 remitters stayed in remission at 6 months 🔹 Results remain promising vs standard TRD therapies 🔹 CYB003 from @CybinInc (CYBN) still shows stronger 12-month durability with fewer doses See Robert Sassoon's full update and comparisons in the WTR report! $CYBN $GHRS #MentalHealth #Biotech #DepressionTreatment #SmallCap #Stocks #Investing #Healthcare #HealthTech #Psychedelics #WTR #Research
0 · Reply
Quantumup
Quantumup Jul. 24 at 7:18 PM
Citizens y'day reiterated $GHRS Market Outperform-$39 and said, "Focus remains on ongoing FDA engagement with strong Phase 2b and OLE data reinforcing the blockbuster potential of GH001" $ATAI $JNJ $CMPS CYBN $MNMD Citizens added, "We reiterate our Market Outperform rating and $39 risk-adjusted, DCF-derived price target on GH Research. This morning, GH Research announced that it has received feedback from the FDA on the recent submission to address the clinical hold for GH001. Only one topic, the relevance respiratory tract histology findings in rats, remains open with the FDA and all other items for the hold have been resolved. We remain comfortable that the rat findings are species specific. Also today, the company announced final results from the open-label extension portion of the Phase 2b trial in treatment-resistant depression, with a remission rate consistent with interim results disclosed in February."
1 · Reply
twiggs462
twiggs462 Jul. 23 at 5:14 PM
$ATAI > $GHRS ATAI is the 5meo winner. FDA will call the race soon enough. BUT THE SQUEEZE will be in effect prior. True rocket ship power.
0 · Reply